Originally posted here:
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
Related Post
- Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating... - June 15th, 2024
- Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress - June 15th, 2024
- Intellia Therapeutics Names Brian Goff to its Board of Directors - June 15th, 2024
- BetterLife Announces Closing of a Private Placement - June 15th, 2024
- Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market - June 15th, 2024
- ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at... - June 15th, 2024
- Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of... - June 15th, 2024
- Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress - June 15th, 2024
- Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors - June 15th, 2024
- Disc Medicine Announces Underwritten Offering of Common Stock - June 15th, 2024
- Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid... - June 15th, 2024
- FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc. - June 15th, 2024
- TALVEY®▼ (talquetamab) demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma - June 15th, 2024
- LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial - June 15th, 2024
- Renovaro, Inc. Announces $10 million in Equity Committed - June 15th, 2024
- Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut - June 15th, 2024
- Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 - June 15th, 2024
- Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in... - June 15th, 2024
- Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European... - June 15th, 2024
- FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements; Completes Steps it Believes are... - June 15th, 2024
- Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders - June 5th, 2024
- Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference - June 5th, 2024
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast - June 5th, 2024
- Clene to Present at the Emerging Growth Conference - June 5th, 2024
- Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - June 5th, 2024
- Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024 - June 5th, 2024
- Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts - June 5th, 2024
- Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024 - June 5th, 2024
- VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 - June 5th, 2024
- Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress - June 5th, 2024
- First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial - June 5th, 2024
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs - June 5th, 2024
- Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024 - June 5th, 2024
- Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors - June 5th, 2024
- XTL Entered Definitive Agreement to Acquire The Social Proxy - June 5th, 2024
- Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate - June 5th, 2024
- Late Breaking Poster Shows a Novel Oral Insulin Sensitizer Azemiglitazone (MSDC-0602K) Could Substantially Preserve Lean Muscle in Combination with... - June 5th, 2024
- Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024 - June 5th, 2024
- Intercept Presents New Data on the Results of OCA-Bezafibrate Combination Therapy in PBC After Six Months of Treatment in Late-Breaking Poster... - June 5th, 2024
- InflaRx Hosts R&D Event Highlighting the Promise of INF904 - June 5th, 2024
- 7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic - June 4th, 2024
- Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment... - June 4th, 2024
- Conor McGregor and Virat Kohli Collaborate to Launch TIDL's Innovative Pain Relief Products in India - June 4th, 2024
- Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility - June 4th, 2024
- Late-breaking results from PALOMA-2 study of subcutaneous RYBREVANT®▼ (amivantamab) in combination with lazertinib show clinically meaningful... - June 4th, 2024
- BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients - June 4th, 2024
- Invivyd to Participate at the Jefferies Global Healthcare Conference - June 4th, 2024
- BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 - June 4th, 2024
- Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 - June 4th, 2024
- Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 - June 4th, 2024
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation - June 4th, 2024
- FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of... - June 4th, 2024
- PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024 - June 4th, 2024
- CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard... - June 4th, 2024
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 4th, 2024
- FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165... - June 4th, 2024
- Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool - June 4th, 2024
- Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed... - June 4th, 2024
- DARZALEX® (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly... - June 4th, 2024
- Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data - June 4th, 2024
- Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase... - June 2nd, 2024
- AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing... - June 2nd, 2024
- Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency - June 2nd, 2024
- Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine - June 2nd, 2024
- Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous... - June 2nd, 2024
- Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine - June 2nd, 2024
- Mainz Biomed Reports Results of 2024 Annual General Meeting - June 2nd, 2024
- CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting - June 2nd, 2024
- Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT®▼... - June 2nd, 2024
- RYBREVANT®▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with... - June 2nd, 2024
- Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - June 2nd, 2024
- Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib - June 2nd, 2024
- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical... - June 2nd, 2024
- Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting - June 2nd, 2024
- Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting - June 2nd, 2024
- Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid... - June 2nd, 2024
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in... - June 2nd, 2024
- Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in... - June 2nd, 2024
- Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical... - June 2nd, 2024
- Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive... - June 2nd, 2024
Recent Comments